Ovoca Gold (GB:OVB) has released an update.
Ovoca Bio, a biopharmaceutical company specializing in women’s health, reported solid financial health in their interim report for the first half of 2024, with cash reserves of €2.9 million. Despite setbacks from a Phase II trial in 2023, the company is actively optimizing its corporate structure and seeking new opportunities, with expected cash refunds from Australian authorities to be received by Q4 2024. Management thanks its team and board for their ongoing support as they navigate the future.
For further insights into GB:OVB stock, check out TipRanks’ Stock Analysis page.
